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Abstract
Background: Stem cells from human exfoliated deciduous teeth (SHED) have recently attracted attention as novel
multipotential stem cell sources. However, their application is limited due to in vitro replicative senescence. Ectopic
expression of telomerase reverse transcriptase (TERT) is a promising strategy for overcoming this replicative
senescence. Nevertheless, its potential application and the phenotype as well as tumorigenicity have never
been assessed in SHED.
Methods: TERT expression was stably restored in SHED (TERT-SHED) isolated from healthy children aged 6–8
years using lentiviral transduction with a puromycin selection marker. The expression of TERT was detected
using reverse transcription polymerase chain reaction, Western blot and immunofluorescence. Surface markers of SHED
were detected by flow cytometry. Enzyme-linked immunosorbent assay was used to assess senescence-associated
β-galactosidase, while CCK-8 methods were used to examine the proliferation capacity of SHED and TERT-SHED
at different passages. Moreover, multilineage differentiation, karyotype, colony formation in soft agar, and tumor
formation in nude mice of SHED and TERT-SHED were also examined.
Results: Lentiviral transduction induced stable TERT expression even in SHED at the 40th passage. TERT-SHED
showed robust proliferation capacity and low concentration of β-galactosidase. Although they had some different
biomarkers than early passage SHED, TERT-SHED at late passage showed similar mutilineage differentiation as
TERT at early passage. Moreover, TERT-SHED at late passage showed normal karyotype, no soft agar colony
formation, and no tumor formation in nude mice.
Conclusions: TERT-immortalized SHED may be a promising resource for stem-cell therapy, although attention
should be paid to the biological behavior of the cells.
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Background
Tissue engineering depends on the association of stem
cells, growth factors, organ tissue culture, and tissue en-
gineering materials [1]. In dentistry, regenerative strat-
egies are of great relevance because of hard dental tissue
damage, especially as a result of caries lesions, trauma,
or iatrogenic procedures. The principles of regenerative
medicine can be applied to endodontic tissue engineer-
ing. Regeneration of the pulp-dentin complex will allow
natural replacement of damaged or missing tooth struc-
tures through the activation of tissue-specific stem cells
of animal origin or transplantation of stem cells isolated
and ex vivo expanded [2]. Stem cells can be found to be
quiescent in their niche in all tissues of an adult organ-
ism. In response to organ injury, these cells initiate their
proliferation and differentiation with the aim of healing
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injured tissue. Among various dental pulp stem cells
(DPSCs), stem cells from human exfoliated deciduous
teeth (SHED) have recently attracted attention as novel
multipotential stem cell sources [3]. The loss of primary
teeth creates the perfect opportunity to recover and
store this convenient source of stem cells. Isolating
SHED is simple, painless and convenient, and involves
little or no trauma. These immature stem cells are im-
portant in the regeneration and repair of craniofacial de-
fects, tooth loss, and bones because of their capability to
proliferate and differentiate [4]. SHED generate rapidly
and grow faster than adult stem cells, thus suggesting
that they are less mature. SHED are postnatal stem cells
capable of differentiating into osteogenic, odontogenic,
adipogenic, and neural cells [5].
Although they have high self-renewal capacity, dental
stem cells such as SHED will ultimately enter an irrevers-
ible proliferation-arrested state referred to as replicative
senescence after long term in vitro culture under culture
stresses, such as hyperoxia and elevated temperature [6].
Several strategies have been explored to overcome this
replicative senescence, such as treatment of SHED with
benzopyrene (BaP), radiation, or ectopic expression of
viral oncogenes [7]. Long-term treatment with carcino-
genic agents such as BaP results in transformation of cells
as evidenced by chromosomal abnormalities, anchorage-
independent growth in soft agar, and tumorigenicity in
nude mice [8]. Radiation has been shown to be sufficient
for immortalization of breast epithelial cells [9]. However,
immortalization by radiation occurs relatively infrequently
and results in morphological transformation of cells [9]
and formation of tumors in nude mice [10]. A number of
viral oncogenes, including simian virus-40 (SV40) large
T-antigen, adenovirus E1A and E1B, polyoma T-antigen,
and papillomavirus E6 and E7, have also been used to
immortalize human cells [11–13]. Although immortalized
cell lines have been successfully established by transfecting
cells with viral oncogenes, inactivation of protein products
of the tumor suppressor p53 and retinoblastoma (Rb)
[14, 15], introduction of karyotypic instability, and
transformation of phenotype have been reported in
many studies [16, 17].
The cellular senescence and the lifespan depend on
the loss rate of telomeres during each cell division and
the primary length of the telomere [18]. Telomerase re-
verse transcriptase (TERT; catalysis subunit of telomerase)
plays critical roles in the maintenance of telomere length
during cell division [19–21]. It has been demonstrated that
telomerase reconstitution via TERT expression could ex-
tend the telomere, prolong the lifespan of cells, and even
immortalize cells [22, 23]. It has been established that the
expression of TERT is a key step in human cellular prolif-
eration, differentiation, and apoptosis. Moreover, recent
findings indicate that TERT regulates stem cell properties
in stemness sustaining and self-renew characterizations
[24, 25]. While ectopic expression of TERT does signifi-
cantly lengthen the lifespan of cells, enhanced telomerase
activity is also a feature of many types of tumors and
malignancies [26, 27]. The potential tumorigenicity of
TERT-expressed stem cells remains controversial [27–29].
Therefore, the tumorigenicity of TERT expression in hu-
man stem cells needs to be further validated.
Our primary goal in this study was to create an im-
mortalized SHED cell line by stable expression of TERT.
Moreover, we assessed the multipotency and the poten-
tial tumorigenicity of our immortalized SHED cell line.
Methods
Subjects and cell culture
The SHED were obtained from the deciduous teeth of
children aged 6–8 years. Every patient involved in the
study consented to participate in the study and signed
the paper consent. This study was approved according
to guidelines set by the Ethic Committee of the Dental
Hospital, Xi’an Jiaotong University. The deciduous anter-
ior teeth used in this study were near natural exfoliation,
with less than one third of the root remaining, and
without any deep caries, restoration, periapical lesions,
or internal resorption. After extraction, pulp tissues from
the deciduous teeth were extirpated using a barbed broach
(Mani, Utsunomiya Toshi-ken, Japan), washed with
phosphate-buffered saline (PBS; Invitrogen, Carlsbad,
CA, USA), and then treated with collagenase type I
(3 mg/ml; Invitrogen) and dispase (4 mg/ml; Invitrogen)
for 30 min at 37 °C; they were then filtered through a 70-
μm cell strainer. The SHED were cultured in a DMEM/
F12 medium supplemented with 15 % fetal bovine serum,
2 mmol/l L-glutamine, 100 μmol/l L-ascorbic acid-2-
phosphate, 100 U/ml penicillin, 100 μg/ml streptomycin,
and 0.25 μg/ml amphotericin B. After 7 days, cell colonies
were observed. Individual cell colonies were collected by
the filter paper enzyme digestion method. The derived
cells were SHED.
Cloning of TERT in lentiviral expression plasmid and
lentiviral production
pCMV6-XL5 plasmid (OriGene Technologies, Beijing,
China) containing full-length cDNA of human TERT
(3.6 kb) [Genbank:NM_198253.2] was amplified in DH5α
E. coli strain. The cDNA clone of TERT and GV166 lenti-
viral vector (GeneChem Co., Ltd., Shanghai, China) were
digested by a cocktail of EcoR I and Sal I (New England
Biolabs, Ipswich, USA). The subsequent fragments were
purified and recombined by T4 ligase (New England Bio-
labs) and then transformed into DH5α E. coli selecting for
ampicillin resistance. The transformants were screened for
correct insertion/orientation of the TERT fragment by re-
striction analysis. GV166 vector not recombined with
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TERT was used as the control vector. For lentiviral
production, the GV166-TERT or control plasmid was
co-transfected into 293FT cells with Lenti-Easy Pack-
aging Mix (GeneChem Co., Ltd.) at a 1:3 ratio using Li-
pofectamine™ reagent (Invitrogen). Forty-eight hours
after transfection, the virus-containing supernatant was
harvested and stored in aliquots at −80 °C. All cell cul-
ture procedures were performed under biosafety level 2
conditions.
Transduction of SHED with lentiviral vectors
Cells were plated 24 h before transduction at a density
of 5 × 104 cells per well in six-well plates in the presence
of 5 μg/ml polybrene. Transduction of SHED was carried
out with TERT or control lentivirus at a multiplicity of in-
fection (MOI) of 65. Transduced cells were passaged, and
selected with puromycin (1.5 mg/ml) for 5 days.
Extraction of total RNA and RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s proto-
col, and RNase-free DNase I was used to remove DNA
contamination. Reverse transcription (RT) was performed
with 2 μg total RNA using M-MLV Reverse transcriptase
(Promega, Madison, WI, USA) to synthesize first-strand
cDNA according to the manufacturer’s recommendation,
followed by cDNA amplification using the specific primers
for TERT and the β-actin primer. Primers used in this study
were as follows: 5′-AGAGTGTCTGGAGCAAGTTG-3′
(forward) and 5′-GGATGAAGCGGAGTCTGG-3′ (re-
verse) for TERT; 5′-ATCGTGCGTGACATTAAGGAG
AAG-3′ (forward) and 5′-GAGGAAGGAAGGCTGG
AAGAGTG-3′ (reverse) for β-actin; and the corre-
sponding polymerase chain reaction (PCR) products
were 140 bp and 179 bp, respectively.
Western blot
Cells were lysed in RIPA lysis buffer, and the lysates were
harvested by centrifugation (13,523 × g) at 4 °C for
30 min. Approximately 20 μg protein samples were then
separated by electrophoresis in a 12 % sodium dodecyl
sulfate polyacrylamide gel and transferred onto a polyvi-
nylidene fluoride membrane. After blocking the non-
specific binding sites for 60 min with 5 % non-fat milk,
the membranes were incubated overnight at 4 °C with a
mouse monoclonal antibody against human TERT
(Abgent, USA, at a 1:1000 dilution). The membranes
were then washed three times with TBST (tris-buffered
saline with tween-20) for 10 min and probed with the
horseradish peroxidase (HRP)-conjugated rabbit anti-
mouse IgG antibody (Immunology Consultants La-
boratory, USA, at a 1:2000 dilution) at 37 °C for 1 h.
After three washes, the membranes were developed by
an enhanced chemiluminescence system (Cell Signaling
Technology, Danvers, MA, USA). A rabbit polyclonal anti-
body against human β-actin (Abcam, UK, at a 1:10000)
was set as the inner control.
Immunofluorescence staining
Cells were fixed in 4 % paraformaldehyde, permeabilized
with 0.1 % Triton1-X100, and blocked with 10 % horse
serum in PBS for 1 h. The TERT antibody was prepared
at 1:100 dilution and further incubated with the samples
for 18 h at 4 °C. After washing with PBS, the cell was in-
cubated with FITC-labeled goat antimouse antibody
(Invitrogen) at 1:500 dilution for 45 min. Cells were also
counterstained with DAPI. The fluorescence was evalu-
ated by fluorescence microscope (Apotome).
Detection of surface markers by flow cytometry
The stem cell nature of SHED was analyzed using flow
cytometry. Cells cultured with basal medium before cell
differentiation were harvested using trypsin and washed
twice with PBS. For cell surface staining, cells were fixed,
washed and incubated with FITC-conjugated monoclo-
nal or polyclonal antibodies against CD34, CD45, CD146
or STRO-1 (all Biolegend, CA, USA). For intracellular
staining, cells were fixed and permeabilized using the Fix &
Perm kit (Invitrogen), then washed and incubated with
FITC-conjugated monoclonal or polyclonal antibodies
against Oct-4 or Nanog (both Biolegend). FITC-conjugated
IgG (Biolegend) was used as a negative control. The cells
were analyzed using a FACScan flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA).
Multilineage differentiation assays
In vitro osteogenic differentiation of SHED was performed
as previously published [30] using 100 nM dexametha-
sone, 10 mM β-glycerophosphate, and 50 M L-ascorbic
acid-2-phosphate (Sigma). A total of 5 × 103 cells/well
were seeded on to a six-well plate. After 16 days cells were
assayed by von Kossa staining using a standard protocol.
Adipogenic differentiation was accomplished as previously
published [30] by 1 M dexamethasone, 0.2 mM indometh-
acin, 0.1 mg/ml insulin, and 1 mM 3-isobutyl-1-methyl-
xanthin (IBMX) (Sigma). The maintenance medium
consisted of 0.1 mg/ml insulin in standard medium. A
total of 4 × 103 cells/well were seeded on to a 12-well
plate. Stimulation was started when cells reached full con-
fluency. Cells were grown for 5 days in induction medium
and thereafter for 2 days in maintenance medium, and
were then switched to induction medium again. After
16 days of stimulation, the cells were assayed by oil
red staining using a standard protocol. Chondrogenic
differentiation was achieved in aggregate cultures as
previously published [30] with 100 nM dexamethasone,
1 mM pyruvate, 195 M L-ascorbic acid-2-phosphate,
350 M L-proline, 1.25 % (v/v) insulin-transferrin-selenious
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acid mix (ITS, 100×), 5.35 g/ml linolic acid, 1.25 mg/ml
bovine serum albumin (BSA; Sigma), and transforming
growth factor-3 (TGF-3, 10 ng/ml; R&D Systems, Minne-
apolis, MN, USA). A total of 2.5 × 105 cells were used per
pellet. Sections (12 μm) were cut with a cryostat vacutome
HM 200 OM (Microm, Walldorf, Germany). Anionic
sulfated proteoglycans were detected by toluidine blue
metachromasia. Slices were stained in 1 % toluidine
blue solution (Sigma, Munich, Germany) and 1 % sodium
tetraborate (Sigma).
Real-time PCR
Total RNA and cDNA of differentiation-induced cells were
prepared according to the above-mentioned protocols. Dif-
ferentiation markers and GAPDH were amplified by quan-










ATGCCATACGTCCTCA-3′; COL2A1 forward: 5′-CCAG
TTGGGAGTAATGCAAGGA-3′, reverse: 5′-ACACCAG
GTTCACCAGGTTCA-3′; GAPDH forward: 5′-CTCCTC
CTGTTCGACAGTCAGC-3′, reverse: 5′-CCCAATACGA
CCAAATCCGTT-3′. Gene-specific amplification was per-
formed in an ABI 7900HT real-time PCR system (Life
Technologies, Carlsbad, CA) with a 15-μl PCR mix con-
taining 0.5 μl cDNA, 7.5 μl 2 × SYBR Green master mix
(Invitrogen), and 200 nM of the appropriate primers. The
mix was preheated at 95 °C for 10 min and then amplified
in 45 cycles of 95 °C for 30 s and 60 °C for 1 min. The reso-
lution curve was measured at 95 °C for 15 s, 60 °C for 15 s,
and 95 °C for 15 s. The Ct (threshold cycle) value of each
sample was calculated, and the relative mRNA expression
was normalized to the GAPDH value (2–ΔΔCt method). The
final expression value of differentiation markers was stan-
dardized according to that of control cultures.
Senescence-associated β-galactosidase assay by ELISA
Cells (1 × 106) were lysed and the supernatant was
collected by centrifuge. The activity of β-galactosidase
(β-GAL) in SHED was assessed using the human β-GAL
enzyme-linked immunosorbent assay (ELISA) Kit (CSB-
E09463h, Cusabio, China) according to the manufacturer’s
recommendations.
Proliferation assay
Cells were plated at a density of 1 × 103/well in 96-well
plates and cultured in basal medium. A CCK-8 assay
was performed twice a day according to the cell count-
ing kit protocol (Keygen Biotech, Nanjing, China) for 12
consecutive days. The values for each well were spectro-
photometrically measured at 450 nm.
Cytogenetic analysis
Metaphase spreads were prepared from exponentially
growing TERT-SHED at various passages. Cells were
harvested and fixed following standard protocols [31].
Chromosome analysis was performed using the GTG-
banding technique [31]. Fifteen metaphases captured by
a CCD camera were analyzed and karyotyped using the
CytoVision system (Leica Biosystems, Nussloch, Germany).
Chromosome identification and karyotype description were
made in accordance with the International System for
Chromosome Nomenclature [32].
DNA isolation and PCR analysis of CDKN2A
Genomic DNA from SHED P4, and TERT-SHED P20
and P40 was extracted using the QIAamp DNA Mini
Kit (QIAGEN, Duesseldorf, Germany) according to the
manufacturer’s recommendations. The exon 2 of the
CDKN2A gene was amplified in an ABI GeneAmp 9600
PCR system using the following primers: forward: 5′-CC
TGGCTCTGACCATTCTGTTC-3′, reverse: 5′-GCTTTG
GAAGCTCTCAGGGTAC-3′. The PCR mixture contained
100 ng genomic DNA, 10 μl 2 × Taq PCR Master Mix
(TIANGEN Biotech, Beijing, China), and 0.1 pmol/μl of
each primer in a total 20 μl volume. The PCR cycling con-
ditions were 94 °C (2 min) for 1 cycle, 94 °C (30 s), 55 °C
(40 s), 72 °C (2 min) for 36 cycles, and a final extension of
72 °C (10 min). The PCR products were 386 bp in length.
Soft agar assay
TERT-SHED or tongue cancer cells (Tca-8113; 2500
cells) in logarithmic growth phase were trypsinized and
suspended into a single cell suspension in 0.5 ml 0.8 % top
agar solution (37 °C). The cells were aliquoted on the top
of a pre-prepared 1 ml 1.2 % base agar layer, and then in-
cubated for 28 days at 37 °C with 5 % CO2. The well plates
were stained with 0.005 % crystal violet for 2 h before a
photograph was taken under a microscope [33].
Tumorigenicity in nude mice
Twenty athymic nude mice were divided into four
groups: SHED P2, TERT-SHED P20, Tca-8113, and PBS
control. Cells (2 × 106) of each cell type were suspended
in 200 μl PBS and injected subcutaneously into the fore
and hind limb armpit under general anesthesia. Mice
were sacrificed after 8 weeks by CO2 overdose. All pro-
cedures were performed according to animal protection
legislation and approved by the Ethics Committee of the
Dental Hospital, Xi’an Jiaotong University. Photographs
were taken every week for macroscopic evaluation. Skin
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and underlying soft tissue of the relevant area were dis-
sected 8 weeks after cell implantation. Slides were pre-
pared and stained with hematoxylin and eosin dye, and
investigated for possible tumor growth [34].
Statistical analysis
The data for β-GAL concentration and proliferation
were expressed as mean ± standard deviation (SD). One-
way proliferation data were used to compare the differ-
ence in β-GAL and followed by Fisher’s LSD post hoc
test. Repeated measurement analysis of variance was
used to compare the differences between proliferation
curves. All statistical analyses were performed using




The morphology of SHED was analyzed under phase
contrast microscope (Fig. 1). SHED spread along the
surface of the culture plates, showing rapid growth
within the first week. Cell colonies were seen from the
fifth day, as the cells grew to confluence at 10–14 days.
Expression of TERT in SHED after lentiviral transduction
We first analyzed the expression of TERT in SHED after
stable lentiviral transduction using Western blot and
immunofluorescence. As shown in Fig. 2, TERT trans-
duction remarkably restored the expression of TERT in
SHED (TERT-SHED), while the control virus did not
show TERT expression (SHED).
Expression of TERT in TERT-SHED during passage
We further analyzed the expression of TERT during the
passage of TERT-SHED using RT-PCR and Western blot.
As shown in Fig. 3, TERT expression remained stable even
in the 40th passage.
Surface markers of SHED
The flow cytometry analysis was applied to quantify the
expression ratios of specific surface antigens in SHED and
TERT-SHED. The SHED at the fourth passage (SHED P4)
showed robust expression of CD146 (90.45 %), STRO-1
(72.10 %), CD34 (65.76 %), and Oct-4 (85.16 %), weak ex-
pression of Nanog (13.84 %), and nearly negative expres-
sion of CD45 (3.79 %) (Fig. 4a). The TERT-SHED at the
20th passage (SHED P20) showed decreased expression of
CD146 (48.51 %), STRO-1 (58.47 %), Oct-4 (10.48 %),
Nanog (7.64 %), and CD34 (3.71 %) (Fig. 4b).
Multilineage differentiation of SHED
The multilineage differentiation potential of SHED was
measured by differentiation induction assay. SHED P4
could different into osteogenic, adipogenic, and chondral
cell lineages, as revealed by positive staining for Alizarin
Red S, Oil Red O and Toluidine blue, respectively
(Fig. 5a–c). Moreover, TERT-SHED P20 showed similar
differentiation capacity to SHED P4 (Fig. 5e–g). Further-
more, real-time PCR analysis confirmed that TERT-SHED
P20 and SHED P4 had similar expression of osteogenic
(ALP and BSP), adipogenic (LPL and PPAR-γ), and chon-
drogenic (ACAN and COL2A1) differentiation markers
(Fig. 5d and h).
Cell senescence and proliferation capacity of SHED
β-GAL activity at pH 6 is a known characteristic of senes-
cent cells which is not found in presenescent, quiescent or
immortal cells. We first examined the senescence marker,
β-GAL, in SHED and TERT-SHED at different passages.
As shown in Fig. 6a, the concentration of β-GAL in the
20th passage of SHED (SHED P20) was as 120 times that
in SHED P4. However, β-GAL concentration remained at
a very low level in the 40th passage of TERT-SHED
(TERT-SHED P40). The proliferation capacity of SHED
was detected by CCK-8 assay. As shown in Fig. 6b, the
proliferation capacity of SHED at late passage (P20) sig-
nificantly decreased. However, TERT-SHED P40 had
similar proliferation potential to the early passage (P4)
of SHED.
Cytogenetic of TERT-SHED
Atypia is one of the major characteristics of cancer.
We therefore analyzed the karyotype of TERT-SHED
at late passage (P20). As shown in Fig. 7a, no polyploid
mutation or chromosomal deletion was found in
TERT-SHED P40.
Fig. 1 Typical cell morphology of SHED under phase contrast
microscope. SHED revealed a typical fibroblast-like morphology.
Scale bar = 50 μm
Yin et al. Stem Cell Research & Therapy  (2016) 7:50 Page 5 of 11
Integrity of genomic CDKN2A
Since a deletion of the CDKN2A gene locus has been de-
scribed after ectopic TERT expression using retroviral
vectors [35], we analyzed the integrity of CDKN2A. PCR
amplification yielded a band of the expected size for
SHED P4, TERT-SHED P20 and TERT-SHED P40
(Fig. 7b).
Colony formation of TERT-SHED
The soft agar colony formation assay is a common
method to monitor anchorage-independent growth. We
thus examined the colony formation of TERT-SHED
P20. As shown in Fig. 7c, only a single cell was noticed
growing in soft agar in the culture of TERT-SHED P20,
while cell aggregates were formed in the culture of tongue
cancer cells (Tca-8113).
Tumorigenicity of TERT-SHED in nude mice
We further assessed tumor formation of TERT-SHED
P20 in nude mice. As shown in Fig. 7d, no tumor formation
was seen in TERT-SHED P20. However, tumor formation
was noticed after Tca-8113 cell inoculation.
Discussion
In this study, we established a method to immortalize
SHED using ectopic stable expression of TERT by lenti-
viral vector. We found that TERT-SHED showed a ro-
bust proliferation capacity even in late passages without
cell senescence as indicated by low activity of β-GAL.
Although they had some different biomarkers compared
to early-passage SHED, TERT-SHED at late passage showed
similar mutilineage differentiation to TERT at early passage.
We also assessed the potential tumorigenicity of TERT-
SHED, and found that TERT-SHED at late passage showed
low tumorigenicity, as indicated by normal karyotype, no
soft agar colony formation, and no tumor formation in
nude mice. These data suggest that TERT expression may
be a safe technique for banking SHED for tissue repair.
SHED are mesenchymal-like cells and are an attractive
candidate for use in tissue repair thanks to their multi-
potentiality, easy availability, and immunoprivileged sta-
tus [36]. They do not induce an allogenic reaction and
may even suppress host T-cell proliferation [37], sug-
gesting that cells cultured from a single donor may be
expanded in vitro to form a reserve pool that could be
used for multiple recipients. However, during in vitro
culturing, SHED undergoes replicative senescence and
Fig. 2 Expression of TERT assessed by Western blot (a) and immunofluorescence (b) in SHED at the 20th passage 60 h after control and lentiviral
transduction. Transduction of TERT-recombined lentivirus restored the expression of TERT in SHED and the optimal MOI was 65. Scale bar= 50 μm. TERT
telomerase reverse transcriptase
Fig. 3 Expression of TERT assessed by RT-PCR (a) and Western blot (b) in SHED and TERT-SHED at different passages. SHED showed robust mRNA
and protein expression of TERT even at the 40th passage after lentiviral transduction. P passage, SHED stem cells from human exfoliated deciduous
teeth, TERT telomerase reverse transcriptase
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loses its ability to differentiate over time [38]. Thus,
immortalization of dental stem cells (DSCs) and estab-
lishment of a dental stem cell line are important for
DSC research and regenerative dentistry.
It is generally thought that replicative senescence of
stem cells is a result of genetic instability after critical
shortening of telomeres [39]. Telomerase had the enzym-
atic activity to maintain and elongate telomere length dur-
ing cell division. Ectopic expression of TERT has been
proven in many studies to maintain the telomere length in
different types of cells, thus immortalize cells and prevent
cells from loss of function. Using this approach, stable
Fig. 4 Surface marker of SHED P4 (a) and TERT-SHED P20 (b) as assessed by flow cytometry. TERT-SHED retained the expression of stem cell
markers, such as STRO-1, CD146, and Nanog, at the 20th passage. However, the expression of CD34 and OCT4 was downregulated at the 20th
passage, whereas the expression of CD45 remained at a low level
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expression of TERT prevents replicative senescence in
human mesenchymal stem cells (hMSCs) [40–43], with
a lifespan extension of more than 3 years [44]. These
findings are consistent with our results that stable
TERT expression causes a continuous proliferation of
SHED with a lack of senescence-associated β-GAL stain-
ing in robust cells even in the 40th passage, whereas
untransduced cells went into senescence in the 20th pas-
sage, indicating that TERT expression may be a useful
strategy for immortalizing stem cells.
Usually, long-term in vitro culture of stem cells results
in impaired differentiation capacity [45]. Previous studies
have demonstrated that MSCs overexpressing TERT
exhibit an increased osteogenic differentiation potential
[45], while telomerase deficiency impairs differentiation
of hMSCs [46]. In our study, although TERT-SHED at
late passage showed some decrease in the biomarkers,
its differentiation into osteal, adipic, and chondric cells
was similar to that in SHED at early passage, suggesting
that telomere length maintenance plays an important
role in the differentiation of stem cells.
With the success of immortalization of stem cells by
TERT, concerns about potential malignant transformation
by viral TERT transduction were raised. It has been reported
that long-term culture of TERT-transduced adult MSCs
using a retrovirus resulted in neoplastic transformation
Fig. 5 Multilineage differentiation assay of SHED P4 and TERT-SHED P20. Calcium deposition around cells was stained red by Alizarin Red S
(a and e) after induction; adipose droplets in cells were stained orange by Oil Red O after adipogenic induction (b and f); proteoglycans in
cells were stained blue by Toluidine blue after chondrogenic induction (c and g). The expression of osteogenic, adipogenic, and chondrogenic
differentiation markers were examined using real-time PCR and standardized according to that of control culture (d and h). TERT-SHED P20
showed similar osteogenic, adipogenic, and chondrogenic differentiation to SHED P4. Scale bar = 50 μm. P passage, SHED stem cells from human
exfoliated deciduous teeth, TERT telomerase reverse transcriptase
Fig. 6 Comparison of β-GAL expression and proliferation capacity of SHED and TERT-SHED at different passages. a TERT-SHED showed low β-GAL
expression at a late passage (40th passage; P40), whereas SHED P20 showed senescence as indicated by remarkably high β-GAL expression. b
TERT-SHED at late passages (20th and 40th passages; P20 and P40) showed a significantly stronger capacity for proliferation than SHED at the
fourth passage (P4). *P < 0.05. OD optical density, SHED stem cells from human exfoliated deciduous teeth, TERT telomerase reverse transcriptase
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[26, 35]. Insertional mutagenesis by long terminal re-
peat (LTR) has been a limitation of retroviral gene
transfer [35] since oncogenesis occurred at an unex-
pected high frequency in the X-SCID gene therapy trial.
However, so far, all available data suggest that lentiviral
vectors are safe vehicles for ex vivo gene therapy and
no adverse events have been reported upon transplant-
ation of lentivirus vector-transduced cells [47]. The
major reason for the low genotoxicity of lentiviral vec-
tors may be the lack of transcriptionally active LTR. On
the other hand, telomere length maintenance plays crit-
ical roles in preventing chromosomal instability and sub-
sequent carcinogenesis. Markedly elevated risks of tumors
(about 11 times that of the general population) are ob-
served in patients with dyskeratosis congenita, a disease
with very short telomeres caused by germline mutations
in the components of the telomerase complex [18]. Mouse
models also support the notion that abnormally short
telomere length increases the risk of cancers [48]. Recent
prospective epidemiological studies have demonstrated
that a short telomere is significantly associated with in-
creased cancer incidence and death [49, 50]. Therefore, it
is reasonable that lentiviral vector-mediated TERT expres-
sion had low tumorigenicity in SHED at late passage, as
indicated by no abnormal karyotype, no colony formation
in soft agar, and no tumor formation in nude mice. How-
ever, our findings need to be extended in SHED over hun-
dreds of passages, and emphasize the caution in the use of
TERT-immortalized cells in studies of normal cell biology
and in tissue engineering.
There are several limitations in our study. Like most
laboratory studies [5], our SHED were maintained and
expanded in bovine serum-containing medium, which
raises the concern about its clinical application due to
the high lot-to-lot variability, risk of contamination, and
immune response against xenogenic proteins in bovine
serum [51]. Because of the numerous constituents of
bovine serum, the development of chemically defined
serum-free media with an optimal composition of the
few essential factors is only beginning. Thus, bovine
Fig. 7 Assessment of potential tumorigenicity of TERT-SHED. a TERT-SHED P40 showed no abnormality of karyotype. b PCR application showed
that there was no deletion of CDKN2A in SHED P4, TERT-SHED P20 or TERT-SHED P40. c TERT-SHED P20 showed no colony formation in soft agar,
with Tca-8113 cancer cells as a positive control. Scale bar = 50 μm. d TERT-SHED P20 showed no tumorigenicity in nude mice, with Tca-8113 cells
as a positive control. Scale bar = 50 μm. P passage, SHED stem cells from human exfoliated deciduous teeth, TERT telomerase reverse transcriptase
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serum remains the gold standard medium supplement
for laboratory-scale MSC culture and has been used in
clinical trials approved by the US Food and Drug Ad-
ministration [52]. Recent studies have demonstrated
that human blood-derived components may be an ideal
substitute for bovine serum in the therapeutic application
of stem cells. Therefore, SHED expanded in xeno-free
media are needed for clinical therapy.
Conclusions
In this study, we show that a lentiviral TERT gene trans-
duction could establish a stable SHED cell line that is
completely multipotential; even after long-term in vitro
passaging, no evidence of genetic instability or malignant
biological behavior of these cells was observed. These
findings provide novel strategies to prevent the senes-
cence and maintain the stemness of ex vivo-maintained
SHED for potential clinical therapies, although attention
should be paid to the biological behavior of these cells.
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